Core Insights - 40 Brightwater LLC executed a Sales Purchase Agreement for $10 billion worth of Bitcoin at a 90% Discount / 90% Premium, allowing significant leverage with PEG Global Private Equity X S.A.SICAV-RAIF's Cryptocurrency Lender [1] - A Letter of Intent was signed for a 10-year loan of $21 billion, secured by standby letters of credit from a top 10 European Bank and a $100 million deposit into Oaktree Capital's Escrow, with closing scheduled for October 31, 2025 [2] - Multicorp International, Inc. will receive $10 billion from the $21 billion loan to 40 Brightwater LLC, enhancing its business capabilities and alliances [3] Company Overview - Multicorp International, Inc. is a diversified leader in health, energy, and agriculture, focusing on strategic initiatives for growth and market expansion [4] - Partners Global Equity Group manages $95 billion in assets and is a major player in private equity, venture capital, and credit, providing transformational capital and expertise [5] - Airavata Developers Corporation specializes in commercial and industrial infrastructure construction, emphasizing project management and sustainability [6] - Edwards Capital N.A. LLC is a private Family Office focused on enhancing private wealth through strategic asset class initiatives [7] - 40 Brightwater LLC is a private holding company that acquires private entities and merges them with public companies, leveraging its financial network [8]

Core Insights - STERIS is enhancing its product offerings through new acquisitions and partnerships, currently holding a Zacks Rank 2 (Buy) [1] Group 1: Growth Drivers - The Healthcare segment of STERIS is benefiting from the successful market adoption of its infection prevention consumables and capital equipment, with a reported revenue growth of 5% year over year for Q4 fiscal 2025 [2] - The Applied Sterilization Technologies (AST) division saw a 9% reported growth year over year in Q4 fiscal 2025, driven by a 6% increase in service revenues, with organic revenues in high single digits [3] - STERIS is experiencing increased bioprocessing demand, while global demand from MedTech customers remains stable [3] Group 2: Strategic Acquisitions - STERIS frequently engages in strategic acquisitions and joint ventures, including the recent purchase of surgical instrumentation and sterilization container assets from BD, which enhances its Healthcare product offerings [4] - The company anticipates a strong fiscal year ahead, with reported revenues from continuing operations expected to grow approximately 6-7% in fiscal 2026 [4] Group 3: Stock Performance - Over the past three months, STERIS shares have risen 13.6%, contrasting with an 11.8% dip in the industry, driven by sustained growth in bioprocessing demand and strategic acquisitions [5]

FIRST QUARTER 2025 LEADERSHIP MANDI HOGAN SVP, Marketing WENDY SIMPSON Executive Chairman PAM KESSLER Co-President and Co-CEO CLINT MALIN Co-President and Co-CEO CECE CHIKHALE EVP, Chief Financial Officer, Treasurer and Secretary DAVID BOITANO EVP, Chief Investment Officer GIBSON SATTERWHITE EVP, Asset Management MIKE BOWDEN SVP, Investments BOARD OF DIRECTORS RENEWAL AND SUPPLEMENTAL OPERATING AND FINANCIAL DATA TRANSITION | WENDY SIMPSON | Executive Chairman | | --- | --- | | CORNELIA CHENG | ESG Committe ...